Citadel Advisors’s Rain Oncology Inc. Common Stock RAIN Stock Holding History

Citadel Advisors’s Portfolio RAIN Stock Details RAIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-28,491	Closed	-$34.2K	–	15824
2023 Q4	$34.2K	Buy	28,491 +27,727	+3,629%	+$29.9K	﹤0.01%	12147
2023 Q3	$658	Buy	+764	New	+$837	﹤0.01%	14012
2023 Q2	–	Sell	-10,175	Closed	-$50.9K	–	15531
2023 Q1	$88.9K	Sell	10,175 -21,948	-68%	-$203K	﹤0.01%	11428
2022 Q4	$257K	Sell	32,123 -35,127	-52%	-$221K	﹤0.01%	9638
2022 Q3	$328K	Buy	67,250 +56,888	+549%	+$357K	﹤0.01%	9373
2022 Q2	$57K	Buy	+10,362	New	+$35.6K	﹤0.01%	11853

Citadel Advisors's RAIN Position: Q1 2024 in Review

Citadel Advisors sold out of Rain Oncology Inc. Common Stock (RAIN) in Q1 2024, closing a stake of 28,491 shares — an estimated $34.2K sold.

Citadel Advisors first reported a position in RAIN in Q2 2022 and held it in 6 quarters. The position peaked at $328K in Q3 2022. 0 funds tracked by Wall St. Rank hold RAIN as of Q1 2024.

Citadel Advisors reported no remaining Rain Oncology Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 28,491 Rain Oncology Inc. Common Stock shares in Q1 2024, an estimated $34.2K.
Citadel Advisors first reported a position in Rain Oncology Inc. Common Stock in Q2 2022 and held it in 6 quarters.
Citadel Advisors's Rain Oncology Inc. Common Stock position peaked at $328K in Q3 2022.
0 funds tracked by Wall St. Rank held Rain Oncology Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.